AMP-activated protein kinase modulates cardiac autophagy in diabetic cardiomyopathy

Area of Science:

• Cardiology
• Metabolic Diseases
• Molecular Biology

Background:

• Diabetic cardiomyopathy is a major complication of type I diabetes.
• Reduced AMP-activated protein kinase (AMPK) and cardiac autophagy are observed in diabetic hearts.
• AMPK plays a critical role in regulating cardiac function and autophagy.

Purpose of the Study:

• To investigate the role of AMPK in diabetic cardiomyopathy.
• To determine if metformin, an AMPK activator, can protect the diabetic heart.
• To elucidate the mechanism by which AMPK activation impacts cardiac function in diabetes.

Main Methods:

• Using OVE26 mice with type I diabetes.
• Genetic manipulation of AMPK in cardiomyocytes.
• Treatment with metformin, a known AMPK activator.
• Assessment of cardiac function, autophagy markers, and mortality.

Main Results:

• Diabetic OVE26 mice exhibit reduced AMPK, cardiac dysfunction, and decreased autophagy.
• Genetic inhibition of AMPK exacerbates cardiac dysfunction and increases mortality.
• Metformin treatment significantly enhances cardiac autophagy and preserves cardiac function in OVE26 mice.
• Metformin's protective effects were not observed in dominant negative-AMPK diabetic mice.

Conclusions:

• AMPK activation is crucial for protecting cardiac structure and function in diabetic cardiomyopathy.
• Metformin protects the diabetic heart by enhancing cardiac autophagy through AMPK activation.
• Targeting AMPK represents a potential therapeutic strategy for diabetic heart disease.